SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ATIS is on the move! -- Ignore unavailable to you. Want to Upgrade?

To: Bruce L who wrote (1802)4/29/1999 2:17:00 PM
From: Nicholas P. Acquaviva Jr.  Respond to of 2205
 
Some small analysis recommended it as a buy.



To: Bruce L who wrote (1802)4/29/1999 2:22:00 PM
From: Nicholas P. Acquaviva Jr.  Respond to of 2205
 
techvestllc.com



To: Bruce L who wrote (1802)4/29/1999 2:24:00 PM
From: Rick Strange  Read Replies (2) | Respond to of 2205
 
The word has leaked out that the first half (180) of the trial patients are enrolled. This means that mid-July all of the first 180 patients will have completed treatment. ATIS has announced that these data will be evaluated at this point and if they can show statistical significant clinical benefits, they intend to file at this time.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News